Clofazimine (as part of an optimized background regimen for MDR-TB)
Treatment for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: 100-200mg daily or thrice weekly
Effectiveness
70%
Safety Score
70%
Clinical Trials
40
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
70
DangerousModerateSafe
Treatment Details
Dosage Range
100-200mg daily or thrice weekly
Time to Effect
2-4 months for clinical improvement
Treatment Duration
Clofazimine component 6-12 months, total regimen 9-18 months
Evidence Quality
MODERATENumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
78%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$21,429
Cost per Remission
$21,429
Comparison vs Older MDR-TB regimens without Clofazimine
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Prescription Access Economics
Annual Societal Loss per Patient
$1,500
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$480/year
Time Cost
$240/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$1,000/year
Potential OTC Price
$300/year
Estimated if OTC available
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWClofazimine (as part of an optimized background regimen for MDR-TB) Outcomes
for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov